Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Di Maro, Gennaro ^a   Salerno, Paolo ^a   Unger, Kristian ^b   Orlandella, Francesca M ^a   Monaco, Mario ^c   Chiappetta, Gennaro ^c   Thomas, Gerry ^b   Oczko Wojciechowska, Malgorzata ^d   Masullo, Mariorosario ^e   Jarzab, Barbara ^d   Santoro, Massimo ^a   Salvatore, Giuliana ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

AGR2; Endoplasmic reticulum stress; Migration and invasion; Survival; Thyroid cancer

Indexed keywords

ANTERIOR GRADIENT PROTEIN 2; BORTEZOMIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; PROTEIN; PROTEIN DISULFIDE ISOMERASE; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; THYROID CARCINOMA; THYROID CELL; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; CARCINOMA; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; GENE SILENCING; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; BORONIC ACIDS; BORTEZOMIB; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; ENDOPLASMIC RETICULUM STRESS; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM INVASIVENESS; OXIDATION-REDUCTION; PROTEIN DISULFIDE-ISOMERASES; PROTEINS; PYRAZINES; THYROID NEOPLASMS; UP-REGULATION;

EID: 84903327168     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-160     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013, 63:11-30.
2. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
3. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7:569-580.
4. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381:1058-1069.
5. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013, 13:184-199.
6. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007, 67:10148-10158.
7. Aberger F, Weidinger G, Grunz H, Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 1998, 72:115-130.
8. KomiyaT TY, Hirohashi S. Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. Biochim Biophys Acta 1999, 1444:434-438.
9. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett 2011, 304:1-7.
10. Chevet E, Fessart D, Delom F, Mulot A, Vojtesek B, Hrstka R, Murray E, Gray T, Hupp T. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene 2012, 6:2499-2509.
11. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res 2006, 12:1728-1734.
12. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008, 68:7811-7818.
13. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer 2010, 9:149.
14. Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, Song SY, Bae DS, Kim BG, Lee JH. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 2011, 43:91-100.
15. Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G. Expression of AGR2 in non small cell lung cancer. Histol Histopathol 2007, 22:703-708.
16. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein over-expressed in prostate cancer. Genes Chromosomes Cancer 2005, 43:249-259.
17. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005, 24:6646-6656.
18. Hébrant A, Dom G, Dewaele M, Andry G, Trésallet C, Leteurtre E, Dumont JE, Maenhaut C. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 2012, 7:e37807.
19. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, Tronko M, Libert F, Dumont JE, Maenhaut C. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007, 26:7894-7903.
20. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005, 65:1587-1597.
21. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001, 98:15044-15049.
22. Persson S, Rosenquist M, Knoblach B, Khosravi-Far R, Sommarin M, Michalak M. Diversity of the protein disulfide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol 2005, 36:734-740.
23. Benham AM. The protein disulfide isomerase family key players in health and disease. Antioxid Redox Signal 2012, 16:781-789.
24. Kozlov G, Määttänen P, Thomas DY, Gehring K. A structural overview of the PDI family of proteins. FEBS J 2010, 277:3924-3936.
25. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer 2004, 4:966-977.
26. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007, 67:10631-10634.
27. Zhao F, Edwards R, Dizon D, Afrasiabi K, Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B, Lipkin SM. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress inAgr2-/-mice. DevBiol 2010, 338:270-272.
28. Higa A, Mulot A, Delom F, Bouchecareilh M, Nguyên DT, Boismenu D, Wise MJ, Chevet E. Role of pro-oncogenic protein disulfide isomerase (PDI) family member anterior gradient 2 (AGR2) in the control of endoplasmic reticulum homeostasis. J Biol Chem 2011, 286:44855-44868.
29. Ryu J, Park SG, Lee PY, Cho S, Lee do H, Kim GH, Kim JH, Park BC. Dimerization of pro-oncogenic protein Anterior Gradient 2 is required for the interaction with BiP/GRP78. Biochem Biophys Res Commun 2013, 430:610-615.
30. Patel P, Clarke C, Barraclough DL, Jowitt TA, Rudland PS, Barraclough R, Lian LY. Metastasis-promoting anterior gradient 2 protein has a dimeric thioredoxin fold structure and a role in cell adhesion. J Mol Biol 2013, 425:929-943.
31. Gray TA, Murray E, Nowicki MW, Remnant L, Scherl A, Muller P, Vojtesek B, Hupp TR. Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein. Protein Sci 2013, 9:1266-1278.
32. Gupta A, Dong A, Lowe AW. AGR2 gene function requires a unique endoplasmic reticulum localization motif. J Biol Chem 2012, 287:4773-4782.
33. Park SW, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, Barczak AJ, Killeen N, Erle DJ. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci U S A 2009, 106:6950-6955.
34. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J Biol Chem 1979, 254:9627-9632.
35. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011, 12:471-480.
36. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006, 91:4013-4021.
37. Schönthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 2013, 85:653-666.
38. Lee CY, Lee MG, Choi KC, Kang HM, Chang YS. Clinical significance of GADD153 expression in stage I non-small cell lung cancer. Oncol Lett 2012, 4:408-412.
39. Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol 2012, 197:857-867.
40. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013, 32:805-818.
41. Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch- Machin MA, Redfern CP. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 2008, 68:5363-5369.
42. Goplen D, Wang J, Enger P, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006, 66:9895-9902.
43. Thomas GA. The Chernobyl Tissue Bank: integrating research on radiation-induced thyroid cancer. J Radiol Prot 2012, 32:77-80.
44. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989, 63:908-911.